What are the maternal and fetal complications associated with pre-existing or gestational diabetes during pregnancy, and what management strategies should be employed?

DIABETES COMPLICATIONS IN PREGNANCY

Diabetes in pregnancy—whether pre-existing type 1, type 2, or gestational—significantly increases risks of maternal complications (preeclampsia, diabetic ketoacidosis, worsening retinopathy) and fetal/neonatal complications (congenital anomalies, macrosomia, intrauterine fetal demise, neonatal hypoglycemia, respiratory distress), with strict glycemic control before and during pregnancy being the single most critical intervention to reduce morbidity and mortality for both mother and child. 1, 2

Maternal Complications

Acute Pregnancy-Related Risks

• Preeclampsia: Risk increases 4-6.6 fold in type 1 diabetes, 3-4 fold in type 2 diabetes, and 1.4-1.6 fold in gestational diabetes compared to non-diabetic pregnancies 3
• Diabetic ketoacidosis: Particularly dangerous in type 1 diabetes during pregnancy, can occur even with moderately elevated glucose (<11 mmol/L or 200 mg/dL) due to accelerated starvation ketosis 3
• Cesarean delivery: Risk increases 4.3-fold (type 1), 3.2-fold (type 2), and 1.4-fold (gestational diabetes) 3
• Spontaneous abortion: Directly correlated with elevated periconceptional A1C 4

Chronic Complication Progression

• Diabetic retinopathy: Pregnancy accelerates progression in women with pre-existing retinopathy; requires dilated eye exam ideally before pregnancy or in first trimester, then monitoring every trimester and for 1 year postpartum 1, 2
• Nephropathy: Can worsen during pregnancy, particularly with pre-existing proteinuria
• Cardiovascular disease: Women with pre-existing diabetes require ECG screening starting at age 35 or with cardiac symptoms/risk factors 5

Fetal and Neonatal Complications

Congenital Anomalies

The most devastating complications occur during organogenesis (5-8 weeks gestation) when many women don't yet know they're pregnant. Elevated periconceptional A1C directly increases risk of:

• Anencephaly and microcephaly
• Congenital heart disease
• Renal anomalies
• Caudal regression syndrome

A1C <6.5% prior to conception is associated with lowest risk of congenital anomalies 6, 2

Growth and Metabolic Complications

• Macrosomia: Risk increases 7.7-fold (type 1), 3.8-fold (type 2), 1.8-fold (gestational diabetes) 3
• Intrauterine fetal demise: Particularly with poor glycemic control 4
• Neonatal hypoglycemia: Prevalence 10-40%, higher with type 1 diabetes, macrosomia, or prematurity; results from fetal hyperinsulinism induced by maternal hyperglycemia 3
• Neonatal hyperbilirubinemia 4
• Respiratory distress syndrome: Risk increases 2.1-fold (type 1), 1.7-fold (type 2), 1.3-fold (gestational diabetes) 3
• Perinatal mortality: Increased 3.6-fold for type 1 diabetes, 1.8-fold for type 2 diabetes 3

Long-Term Offspring Risks

Exposure to hyperglycemia in utero programs the fetus for future metabolic disease:

• Childhood obesity
• Type 2 diabetes and prediabetes
• Hypertension
• Cardiovascular disease 4, 2

Management Strategies to Prevent Complications

Preconception Care (Critical for Pre-existing Diabetes)

All women with diabetes of childbearing potential should receive preconception counseling starting at puberty 2. This is where the greatest impact on reducing complications occurs.

Glycemic targets before conception:

• A1C <6.5% (ideally <6%) to minimize congenital anomalies 6, 2
• A1C <7% is acceptable minimum target 4

Essential preconception interventions 6, 1, 2:

• Discontinue teratogenic medications: ACE inhibitors, ARBs, statins
• Prescribe prenatal vitamins with ≥400 mcg folic acid
• Comprehensive eye exam with ongoing monitoring plan
• Assess for nephropathy (creatinine, urine albumin-to-creatinine ratio)
• Check thyroid function (TSH)
• Effective contraception until glycemic goals achieved
• Discontinue GLP-1 receptor agonists before conception 6

Glycemic Targets During Pregnancy

For pre-existing type 1 or type 2 diabetes 1:

• Fasting glucose: 70-95 mg/dL (3.9-5.3 mmol/L)
• 1-hour postprandial: 110-140 mg/dL (6.1-7.8 mmol/L) OR
• 2-hour postprandial: 100-120 mg/dL (5.6-6.7 mmol/L)
• A1C <6% if achievable without significant hypoglycemia; may relax to <7% if needed 1

For gestational diabetes 4:

• Fasting: <95 mg/dL (5.3 mmol/L)
• 1-hour postprandial: <140 mg/dL (7.8 mmol/L) OR
• 2-hour postprandial: <120 mg/dL (6.7 mmol/L)

Monitoring Strategy

Blood glucose monitoring: Fasting and postprandial self-monitoring is the primary method 1. Postprandial monitoring specifically reduces preeclampsia risk and improves glycemic control.

Continuous glucose monitoring (CGM): In type 1 diabetes, real-time CGM reduces large-for-gestational-age births, neonatal hypoglycemia, and NICU length of stay 1. For type 2 diabetes, evidence is insufficient to recommend CGM over self-monitoring, though it may help achieve targets 6.

Hybrid closed-loop insulin pumps: Suggested for type 1 diabetes over standard pump or multiple daily injections, improving time in range and reducing hypoglycemia 7

A1C monitoring: Check monthly during pregnancy due to altered red blood cell kinetics 1. A1C is a secondary measure—blood glucose monitoring is primary.

Medication Management

Insulin remains first-line for pre-existing diabetes 4. Insulin requirements typically:

• Decrease in first trimester (increased hypoglycemia risk)
• Increase 2-3 fold during second and third trimesters due to insulin resistance 8, 5

For type 2 diabetes: Continue insulin if already prescribed; do not routinely add metformin as it may increase small-for-gestational-age risk despite reducing large-for-gestational-age births 7

For gestational diabetes: Start with lifestyle modifications (diet, exercise); add insulin if targets not met 4. Metformin and glyburide are alternatives when insulin cannot be used, though metformin requires additional insulin in up to 46% of cases 9

Fetal Surveillance and Delivery Planning

Antenatal testing 10:

• Detailed fetal anatomy ultrasound (second trimester)
• Fetal echocardiogram (second trimester)
• Antepartum fetal surveillance starting 32-34 weeks gestation

Delivery timing 10, 7:

• Diet-controlled gestational diabetes: Expectant management to 39-40+6 weeks acceptable
• Medication-controlled diabetes: Delivery at 39-39+6 weeks optimal
• Pre-existing diabetes with complications: Early delivery based on risk assessment; risks may outweigh benefits of expectant management beyond 38 weeks
• Assess for macrosomia; discuss cesarean delivery if estimated fetal weight >4,500 g

Preeclampsia Prophylaxis

Low-dose aspirin 81 mg daily starting between 12-28 weeks (optimally before 16 weeks) for all women with pre-existing diabetes 10

Common Pitfalls to Avoid

1. Failing to provide preconception counseling: Most women with diabetes don't receive preconception care despite its proven benefit in reducing congenital anomalies 2

2. Inadequate contraception until glycemic goals achieved: Unplanned pregnancies with poor glycemic control cause preventable birth defects 2

3. Using A1C as primary monitoring tool in pregnancy: A1C is a secondary measure; pre- and postprandial glucose monitoring is essential 1

4. Not screening for or monitoring retinopathy: Pregnancy accelerates diabetic retinopathy; requires baseline and serial monitoring 1, 2

5. Missing early ketoacidosis in type 1 diabetes: Screen for ketosis even with glucose <200 mg/dL if clinical signs present 3

6. Inadequate postpartum follow-up: Women with gestational diabetes need 75g OGTT at 4-12 weeks postpartum and ongoing diabetes screening 11